Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$102.69 USD

102.69
437,265

-0.38 (-0.37%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $102.72 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Add CVS Health to Your Portfolio Now

by Zacks Equity Research

CVS Health (CVS) is optimistic about synergies from Aetna deal which will help create a robust platform to serve individuals better.

Zacks Equity Research

Solid Global Business Aids NuVasive Amid Pricing Pressure

by Zacks Equity Research

Per NuVasive (NUVA), the international region holds significant growth opportunity. However, pricing pressure is a major headwind.

Zacks Equity Research

Here's Why You Should Invest in PerkinElmer (PKI) Stock Now

by Zacks Equity Research

Focus on emerging markets, improving margins and encouraging guidance provide PerkinElmer (PKI) a competitive edge in the MedTech space.

Zacks Equity Research

Here's Why Investors Should Bet on DexCom (DXCM) Right Now

by Zacks Equity Research

A solid guidance for 2018 and lucrative deals make DexCom (DXCM) a promising investment pick.

Zacks Equity Research

Cardiovascular Systems Gets Approvals in Japan, Widens Suite

by Zacks Equity Research

Cardiovascular Systems (CSII) continues to expand product portfolio to enhance market reach and versatility.

Zacks Equity Research

Here's Why You Should Invest in Wright Medical (WMGI) Now

by Zacks Equity Research

A bullish outlook and a wide array of products make Wright Medical (WMGI) a promising investment pick.

Zacks Equity Research

Here's Why You Should Add Amedisys (AMED) to Your Portfolio

by Zacks Equity Research

Amedisys (AMED) is developing and acquiring new business lines that will complement its existing home care and hospice business.

Zacks Equity Research

Walgreens Counts on International Progress, Strategic Deals

by Zacks Equity Research

We are upbeat about Walgreens' (WBA) recent pact with Alphabet???s life sciences and healthcare segment, Verily, to coordinate on multiple projects with respect to chronic ailments.

Zacks Equity Research

Cardiovascular Systems Treats First Patient With Teleport

by Zacks Equity Research

Cardiovascular Systems (CSII) expands product portfolio to enhance market reach and versatility.

Zacks Equity Research

Here's Why You Should Invest in Hill-Rom (HRC) Stock Now

by Zacks Equity Research

Hill-Rom's (HRC) M&A pipeline continues to be strong.

Zacks Equity Research

Boston Scientific (BSX) to Buy Residual Shares of Millipede

by Zacks Equity Research

Boston Scientific's (BSX) buyout of the leftover stake in Millipede will integrate the latter's IRIS Transcatheter Annuloplasty Ring System in the Structural Heart portfolio of the former.

Zacks Equity Research

Zimmer Biomet (ZBH) Thrives on New Projects, APAC Growth

by Zacks Equity Research

Zimmer Biomet (ZBH) is performing well on the back of its two largest commercial projects, namely the Persona Revision system and the Rosa robotics knee application.

Zacks Equity Research

Ecolab Inks Deal With Clearway for Renewable Power Project

by Zacks Equity Research

Ecolab's (ECL) virtual power purchase agreement with Clearway is part of a broader trend among corporate buyers. This will cover the company???s annual domestic energy use completely.

Zacks Equity Research

Here's Why Investors Should Retain CONMED (CNMD) Stock Now

by Zacks Equity Research

CONMED's (CNMD) steady focus on innovation is indicative of brighter prospects ahead. The company faces cutthroat competition in the niche space.

Zacks Equity Research

Becton, Dickinson's MAX Enteric Viral Panel Cleared by FDA

by Zacks Equity Research

Becton, Dickinson's (BDX) Diagnostic Systems portfolio lends it a competitive edge.

Zacks Equity Research

Here's Why You Should Buy Intuitive Surgical (ISRG) Now

by Zacks Equity Research

A solid outlook for 2018 and strength in robotics make Intuitive Surgical (ISRG) a promising investment pick.

Zacks Equity Research

Medtronic's Growth Across All Lines Aid, Rising Costs Ail

by Zacks Equity Research

Of late, Medtronic (MDT) succeeds in delivering solid top-line growth at CER, backed by balanced growth across major business operation.

Zacks Equity Research

Myriad Genetics Posts Positive Adjusted Vectra Test Data

by Zacks Equity Research

The key finding of Myriad Genetics' (MYGN) study proves that the adjusted Vectra score beats all traditional measures of disease activity to predict radiographic progression in RA patients.

Zacks Equity Research

SYK vs. SRDX: Which MedTech Stock Should Investors Pick?

by Zacks Equity Research

Surmodics (SRDX) scores higher than Stryker (SYK) in terms of current-year revenue projections and fundamentals.

Zacks Equity Research

Varian Medical's (VAR) Halcyon Excluded From Trade Tariffs

by Zacks Equity Research

Recent trade war-related talks are likely to favor Varian Medical (VAR) in the long run.

Zacks Equity Research

Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now

by Zacks Equity Research

Plethora of developments for Becton, Dickinson (BDX); headwinds apprehended in fiscal 2019.

Zacks Equity Research

Here's Why You Should Buy Integer Holdings (ITGR) Stock Now

by Zacks Equity Research

As a result of continued efforts to streamline operations, Integer Holdings (ITGR) has been registering strong profits over the last couple of quarters.

Zacks Equity Research

Here's Why You Should Invest in Genomic Health (GHDX) Now

by Zacks Equity Research

Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now expanding considerably in the international arena.

Zacks Equity Research

Integra Rides on Global Prospects, Hurt by Escalating Costs

by Zacks Equity Research

Integra LifeSciences (IART) aims at investment openings in the Asian market for a faster business boost than in the United States and also to flourish specific parts of its international businesses.

Zacks Equity Research

Quest Diagnostics (DGX) Divests India Business to Strand

by Zacks Equity Research

Quest Diagnostics (DGX) sees lucrative prospects in the U.S. diagnostic testing market.